The main objective of this study is to better understand the biomarkers of patients with abnormal CT (computed tomography) scans of the lungs. Biomarkers are biologic substances found in the blood and may be related to lung disease risk and detection. We intend to enroll volunteers with abnormal CT scans who are being evaluated by a Ralph H. Johnson VA Medical Center pulmonologist as part of their standard medical care. A single blood sample will be obtained, then stored and analyzed to better understand the biomarkers found in blood and to help develop blood-based screening or diagnostic tests. Active participation in this study will be over once a blood sample is obtained. However, we may conduct medical chart reviews of some participants for up to 27 months in order to look at their medical outcomes.
Percepta is a new test that analyzes the cells that line the airways of the lungs to identify patients who are at low risk for lung cancer. It helps physicians decide which patients they can safely treat by follow-up CT scans instead of having to undergo a more invasive procedure, such as surgery.
For many patients, the treatment for advanced lung cancer is often guided by the ability to analyze tumor cells for mutations. The samples of tumor can be taken from lymph glands in the chest through a minimally invasive procedure called endobronchial ultrasound (EBUS) bronchoscopy (flexible tube with a camera, light and ultrasound that is passed into the windpipe through which biopsies can be performed). The purpose of this study is to compare two commercially available EBUS biopsy needles (standard 22-gauge needle and 22-gauge Procore bibeveled needle) to determine if one needle is better than the other at obtaining tumor cells for pathologic and mutational analyses. The study will be performed in patients with known or suspected locally advanced lung cancer during a standard of care EBUS.